Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group.

Tsang RW, Campbell BA, Goda JS, Kelsey CR, Kirova YM, Parikh RR, Ng AK, Ricardi U, Suh CO, Mauch PM, Specht L, Yahalom J.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):794-808. doi: 10.1016/j.ijrobp.2018.05.009. Epub 2018 Jun 20. Review.

PMID:
29976492
2.

The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group.

Constine LS, Yahalom J, Ng AK, Hodgson DC, Wirth A, Milgrom SA, Mikhaeel NG, Eich HT, Illidge T, Ricardi U, Dieckmann K, Moskowitz CH, Advani R, Mauch PM, Specht L, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1100-1118. doi: 10.1016/j.ijrobp.2018.01.011. Epub 2018 Jan 9. Review.

PMID:
29722655
3.

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.

Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, Hoppe B, Oguchi M, Suh CO, Wirth A, Qi S, Davies A, Moskowitz CH, Laskar S, Li Y, Mauch PM, Specht L, Illidge T.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):652-669. doi: 10.1016/j.ijrobp.2017.12.005. Review.

PMID:
29413279
4.

Management and outcomes of women diagnosed with primary breast lymphoma: a multi-institution experience.

Lalani N, Winkfield KM, Soto DE, Yeap BY, Ng AK, Mauch PM, Jimenez RB.

Breast Cancer Res Treat. 2018 May;169(1):197-202. doi: 10.1007/s10549-018-4671-8. Epub 2018 Jan 22.

PMID:
29356916
5.

Reduced Mortality Risk in the Recent Era in Early-Stage Hodgkin Lymphoma Patients Treated With Radiation Therapy With or Without Chemotherapy.

Patel CG, Michaelson E, Chen YH, Silver B, Marcus KJ, Stevenson MA, Mauch PM, Ng AK.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):498-506. doi: 10.1016/j.ijrobp.2017.09.048. Epub 2017 Oct 5.

PMID:
29153331
6.

Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.

Kamran SC, Jacene HA, Chen YH, Mauch PM, Ng AK.

Leuk Lymphoma. 2018 Jun;59(6):1384-1390. doi: 10.1080/10428194.2017.1376745. Epub 2017 Sep 22.

PMID:
28937297
7.

Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG).

Dabaja BS, Zelenetz AD, Ng AK, Tsang RW, Qi S, Allen PK, Hodgson D, Ricardi U, Hoppe RT, Advani R, Mauch PM, Constine LS, Specht L, Li Y, Terezakis SA, Wirth A, Reinartz G, Eich HT, Aleman BMP, Barr P, Yahalom J.

Ann Oncol. 2017 Sep 1;28(9):2185-2190. doi: 10.1093/annonc/mdx334.

PMID:
28911068
8.

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H.

J Natl Compr Canc Netw. 2017 May;15(5):608-638.

PMID:
28476741
9.

Hodgkin lymphoma, version 2.2015.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 May;13(5):554-86.

10.

Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.

Wattson DA, Hunink MG, DiPiro PJ, Das P, Hodgson DC, Mauch PM, Ng AK.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):344-53. doi: 10.1016/j.ijrobp.2014.06.013. Epub 2014 Aug 4.

PMID:
25104066
11.

Four-dimensional versus 3-dimensional computed tomographic planning for gastric mucosa associated lymphoid tissue lymphoma.

Jang JW, Brown JG, Mauch PM, Ng AK.

Pract Radiat Oncol. 2013 Apr-Jun;3(2):124-9. doi: 10.1016/j.prro.2012.05.004. Epub 2012 Jun 12.

PMID:
24674315
12.

Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma.

Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, Silver B, Fisher DC, Marcus KJ, Mauch PM.

J Clin Oncol. 2013 Jun 20;31(18):2282-8. doi: 10.1200/JCO.2012.46.5732. Epub 2013 Apr 22.

PMID:
23610104
13.

Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure.

Russo AL, Chen YH, Martin NE, Vinjamoori A, Luthy SK, Freedman A, Michaelson EM, Silver B, Mauch PM, Ng AK.

Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):121-7. doi: 10.1016/j.ijrobp.2012.12.024. Epub 2013 Feb 12.

PMID:
23414765
14.

Radiotherapy in the management of localized primary cutaneous B-cell lymphoma.

Pashtan I, Mauch PM, Chen YH, Dorfman DM, Silver B, Ng AK.

Leuk Lymphoma. 2013 Apr;54(4):726-30. doi: 10.3109/10428194.2012.723707. Epub 2012 Sep 14.

PMID:
22916994
15.

Influence of new late effects on quality of life over time in Hodgkin lymphoma Survivors: a longitudinal survey study.

Khimani N, Chen YH, Mauch PM, Recklitis C, Diller L, Silver B, Ng AK.

Ann Oncol. 2013 Jan;24(1):226-30. doi: 10.1093/annonc/mds243. Epub 2012 Aug 8.

PMID:
22875834
16.

Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.

Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54. doi: 10.1016/j.ijrobp.2012.01.060. Epub 2012 May 18.

PMID:
22607911
17.

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 May;10(5):589-97.

PMID:
22570290
18.

Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome.

Schoenfeld JD, Mauch PM, Das P, Silver B, Marcus KJ, Stevenson MA, Ng AK.

Ann Oncol. 2012 Jul;23(7):1813-8. doi: 10.1093/annonc/mdr551. Epub 2011 Nov 21.

PMID:
22104573
19.

Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.

Fox AM, Dosoretz AP, Mauch PM, Chen YH, Fisher DC, LaCasce AS, Freedman AS, Silver B, Ng AK.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):277-83. doi: 10.1016/j.ijrobp.2011.05.078. Epub 2011 Oct 20.

PMID:
22019238
20.

Hodgkin lymphoma.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J; NCCN Hodgkin Lymphoma.

J Natl Compr Canc Netw. 2011 Sep 1;9(9):1020-58. No abstract available.

PMID:
21917626
21.

Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy.

Khimani NB, Ng AK, Chen YH, Catalano P, Silver B, Mauch PM.

Ann Oncol. 2011 Apr;22(4):979-84. doi: 10.1093/annonc/mdq548. Epub 2010 Oct 8.

PMID:
20935059
22.

Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation.

Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK.

Blood. 2011 Jan 13;117(2):412-8. doi: 10.1182/blood-2010-06-291328. Epub 2010 Sep 21.

23.

Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.

Chen RC, Chin MS, Ng AK, Feng Y, Neuberg D, Silver B, Pinkus GS, Stevenson MA, Mauch PM.

J Clin Oncol. 2010 Jan 1;28(1):136-41. doi: 10.1200/JCO.2009.24.0945. Epub 2009 Nov 23.

PMID:
19933914
24.

Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors.

Chen AB, Punglia RS, Kuntz KM, Mauch PM, Ng AK.

J Clin Oncol. 2009 Nov 10;27(32):5383-9. doi: 10.1200/JCO.2009.22.8460. Epub 2009 Sep 14.

25.

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.

Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK.

Ann Oncol. 2009 Nov;20(11):1848-53. doi: 10.1093/annonc/mdp071. Epub 2009 Jun 18.

PMID:
19541793
26.

Late effects of Hodgkin's disease and its treatment.

Ng AK, Mauch PM.

Cancer J. 2009 Mar-Apr;15(2):164-8. doi: 10.1097/PPO.0b013e31819e30d7. Review.

PMID:
19390314
27.

A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation.

Rodrigues NA, Killion L, Hickey G, Silver B, Martin C, Stevenson MA, Mauch PM, Ng AK.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1079-83. doi: 10.1016/j.ijrobp.2008.12.053. Epub 2009 Mar 26.

PMID:
19327910
28.

Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma.

Luthy SK, Ng AK, Silver B, Degnan KO, Fisher DC, Freedman AS, Mauch PM.

Ann Oncol. 2008 Dec;19(12):2043-7. doi: 10.1093/annonc/mdn529. Epub 2008 Jul 22.

29.

Hodgkin disease/lymphoma.

Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2008 Jul;6(6):594-622. No abstract available.

PMID:
18597713
30.

A prospective study of pulmonary function in Hodgkin's lymphoma patients.

Ng AK, Li S, Neuberg D, Chi R, Fisher DC, Silver B, Mauch PM.

Ann Oncol. 2008 Oct;19(10):1754-8. doi: 10.1093/annonc/mdn284. Epub 2008 May 7.

PMID:
18467315
31.

Health practice in long-term survivors of Hodgkin's lymphoma.

Ng AK, Li S, Recklitis C, Diller LR, Neuberg D, Silver B, Mauch PM.

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):468-76. doi: 10.1016/j.ijrobp.2007.09.028. Epub 2008 Jan 30.

PMID:
18234434
32.

Nodular lymphocyte-predominant hodgkin lymphoma.

Tsai HK, Mauch PM.

Semin Radiat Oncol. 2007 Jul;17(3):184-9. Review.

PMID:
17591565
33.

Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up.

Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM, Lister TA, Freedman AS.

J Clin Oncol. 2007 Jun 20;25(18):2554-9. Epub 2007 May 21.

PMID:
17515573
34.

Role of radiation therapy in localized aggressive lymphoma.

Ng AK, Mauch PM.

J Clin Oncol. 2007 Mar 1;25(7):757-9. Epub 2007 Jan 16. No abstract available.

PMID:
17228015
35.

Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma.

Tsai HK, Li S, Ng AK, Silver B, Stevenson MA, Mauch PM.

Ann Oncol. 2007 Apr;18(4):672-8. Epub 2007 Jan 11.

PMID:
17218489
36.

The impact of treatment on the risk of second malignancy after Hodgkin's disease.

Ng AK, Mauch PM.

Ann Oncol. 2006 Dec;17(12):1727-9. No abstract available.

PMID:
17151000
37.

Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease.

Ng AK, Li S, Neuberg D, Fisher DC, McMillan C, Silver B, Marcus KC, Stevenson MA, Mauch PM.

Ann Oncol. 2006 Nov;17(11):1693-7. Epub 2006 Oct 3.

PMID:
17018702
38.

Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.

Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK.

J Clin Oncol. 2006 Sep 1;24(25):4116-22.

PMID:
16943528
39.

Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.

Hoppe RT, Advani RH, Bierman PJ, Bloomfield CD, Buadi F, Djulgegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Kaminski MS, Love G, Maloney DG, Mauch PM, Moore JO, Schilder RJ, Weiss L, Winter JN, Yahalom J, Zelenetz AD; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Mar;4(3):210-30. No abstract available.

PMID:
16507269
40.

Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis.

Das P, Ng AK, Earle CC, Mauch PM, Kuntz KM.

Ann Oncol. 2006 May;17(5):785-93. Epub 2006 Feb 24.

PMID:
16500905
41.

Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.

Dillehay GL, Ellerbroek NA, Balon H, Brill DR, Grigsby PW, Macklis RM, Mauch PM, Mian TA, Potters L, Silberstein EB, Williams TR, Wong JC, Gaspar LE; American Society for Therapeutic Radiology and Oncology.

Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1299-307. Epub 2006 Feb 10. No abstract available.

PMID:
16472933
42.

Radiation therapy for orbital lymphoma.

Zhou P, Ng AK, Silver B, Li S, Hua L, Mauch PM.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):866-71. Epub 2005 May 31.

PMID:
15925453
43.

Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative.

Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M 3rd, Gore EM, Tepper JE.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):3-19. Review.

PMID:
15850897
44.

Clinical course of thoracic cancers in Hodgkin's disease survivors.

Das P, Ng AK, Stevenson MA, Mauch PM.

Ann Oncol. 2005 May;16(5):793-7. Epub 2005 Mar 31.

PMID:
15802277
45.

A randomized phase II trial of amifostine for head and neck irradiation in lymphoma.

Ng AK, Hickey G, Li S, Neuberg D, Mauch PM.

Semin Oncol. 2004 Dec;31(6 Suppl 18):20-4.

PMID:
15726518
46.

Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease.

Ng AK, Bernardo MV, Silver B, Van Den Abbeele A, Stevenson MA, Fisher DC, Mauch PM.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):175-84.

PMID:
15629609
47.

FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.

Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD.

Leuk Lymphoma. 2004 Jan;45(1):85-92.

PMID:
15061202
48.

Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease.

Ng AK, Li S, Neuberg D, Silver B, Stevenson MA, Fisher DC, Mauch PM.

Ann Oncol. 2004 Feb;15(2):270-5.

PMID:
14760121
49.

Late complications of therapy of Hodgkin's disease: prevention and management.

Ng AK, Mauch PM.

Curr Hematol Rep. 2004 Jan;3(1):27-33. Review.

PMID:
14695846
50.

Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.

Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM.

Blood. 2002 Sep 15;100(6):1989-96.

Supplemental Content

Loading ...
Support Center